AbbVie (ABBV) Liabilities and Shareholders Equity (2012 - 2026)

AbbVie has disclosed Liabilities and Shareholders Equity across 15 years of filings, most recently posting $136.5 billion for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity changed 0.22% year-over-year to $136.5 billion; the TTM figure through Mar 2026 stood at $541.5 billion (down 2.73% YoY), while the FY2025 annual figure was $134.0 billion, down 0.89% from the prior year.
• Liabilities and Shareholders Equity grew to $136.5 billion in Q1 2026, from $134.0 billion in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for ABBV reached as high as $148.9 billion in Q1 2024 and fell as low as $133.9 billion in Q3 2025.
• The 5-year median for Liabilities and Shareholders Equity is $136.5 billion (2026), against an average of $138.5 billion.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity increased 10.65% — and 2025, when it retreated 8.54%.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $138.8 billion in 2022, then decreased by 2.95% to $134.7 billion in 2023, then climbed by 0.33% to $135.2 billion in 2024, then dropped by 0.89% to $134.0 billion in 2025, then grew by 1.87% to $136.5 billion in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $136.5 billion, $134.0 billion, and $133.9 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.